Friday 23th October 2009

13:00      Welcome and introduction

Decision making therapy of advanced non-small cell lung cancer (Stahel)

13:15      Potential and pitfalls of pathology and molecular analysis (Soltermann)

13:45      EGFR mutation: EGFR pathway and selection of first line therapy with tyrosine kinase inhibitors (Cappuzzo)

14:15      Lung non-squamous cell carcinoma (without EGFR mutations) and good performance status: Choice of chemotherapy, targeted agent and questions of maintenance therapy (Stahel)

14:45      Coffee break            

15:00      Non-small cell lung cancer and poor performance status or co-morbidities: More or less chemotherapy? (Gautschi)

15:30      Oligometastatic non-small cell lung cancer: How to decide about surgery? (Venuta)

16:00      Brain metastasis: The possibilities of radiotherapy (van Houtte)

16:30      Case discussions

17:15      Coffee break

Prevention and early detection (Weder)

17:30      Smoking cessation (Brutsche)

18:00      Lung cancer screening (Boffetta)

18:30      Adjourn

Saturday 24th October 2009

08:30      New TNM Quiz (van Houtte)

Thymoma and selected mediastinal tumors (Weder)

09:00      Pathology of mediastinal tumors (Soltermann)

09:20      Multimodality therapy of mediastinal tumors (Weder)

09:40      Case discussions   

10:00      Coffee break

Second line and further therapy (Stahel)

10:30      How to decide in view of recent developments? (Pless)

11:00      Case discussions

Adjuvant therapy (Weder)

11:30      What are the developments in adjuvant therapy (Betticher)

12:00      Lunch

The heterogeneity of stage III disease and patient selection (Betticher)

13:00      Implication for surgery (Weder)

13:20      Implication for radiotherapy (Plasswilm)

13:40      Implication for chemotherapy (Peters)

14:00      Case presentations